Asston Pharmaceuticals Limited IPO
SME BSE Allotment AwaitedOffer Date: Jul 9, 2025 - Jul 11, 2025
Exp. Premium: 25-30 (20.33%)
₹ 123000 /1000 Shares
Check Allotment*Expected Premium provided in this app is derived from market rumors. It is not a guaranteed indicator of the actual listing price and should be interpreted with caution.
09 Jul, 2025
Open Date11 Jul, 2025
Close Date14 Jul, 2025
Allotment Date16 Jul, 2025
Listing DateIssue Price
₹115-123 per equity shareFace Value
₹10 Per Equity ShareListing at Group
SME BSERegistrar
Maashitla Securities Private LimitedMarket Lot
Individual(Retail)(Min) : 2000 Shares (₹246,000/-)Individual(Retail)(Max) : 2000 Shares (₹246,000/-)
HNI(Min) : 3000 Shares (₹369,000/-)
Lead Manager
Sobhagya Capital Options LtdIssue Size
22,41,000 shares(aggregating up to ₹27.56 Cr)Retail Portion
35%Subscription
186.55 timesAsston Pharmaceuticals IPO Details
Asston Pharmaceuticals Limited IPO is an SME IPO, priced at ₹115-123 per equity share. The equity shares have a face value of ₹10 Per Equity Share each and will be listed on the SME BSE platform. The IPO comprises a total issue of 22,41,000 equity shares, aggregating up to ₹27.56 crores..
The IPO bidding window is open from Jul 9, 2025 to Jul 11, 2025. The allotment is expected to be finalized on Jul 14, 2025, and the tentative listing date is Jul 16, 2025.
The minimum lot size for retail investors is 2000 shares, with a minimum investment of ₹2,46,000. For HNIs, the minimum application size is 3 lots , amounting to ₹ 3,69,000.
Sobhagya Capital Options Ltd is acting as the lead manager to the issue. The registrar of the IPO is Maashitla Securities Private Limited, and
Asston Pharmaceuticals IPO Subscription Details
| As on | QIB / NII | Retail | Total |
|---|---|---|---|
| Shares Offered / Reserved | 4,25,000 / 3,22,000 | 7,46,000 | 14,93,000 |
| Day 1 - 09-07-25 06:00 PM | 3.51 / 0.66 x | 1.22 x | 1.75 x |
| Day 2 - 10-07-25 06:00 PM | 4.47 / 19.67 x | 16.66 x | 13.84 x |
| Day 3 - 11-07-25 06:00 PM | 85.76 / 353.14 x | 172.06 x | 186.55 x |
Asston Pharmaceuticals Valuations
EPS Pre IPO
₹6.90/-EPS Post IPO
₹9.32/-P/E Pre IPO
17.83P/E Post IPO
13.20ROE
50.56%ROCE
51.25%Debt/Equity
0.68RoNW
40.36%PAT Margin
17.27%Price to Book Value
12.07Asston Pharmaceuticals Company Financials All values are in ₹ Cr.
| 31-Mar-25 | 31-Mar-24 | 31-Mar-23 | |
|---|---|---|---|
| Assets | 28.12 | 20.26 | 13.69 |
| Revenue | 25.61 | 15.84 | 7.19 |
| Profit After Tax | 4.33 | 1.36 | 1.06 |
| Net Worth | 10.72 | 6.39 | 1.99 |
| Reserves & Surplus | 4.45 | 5.61 | 1.29 |
| Total Borrowing | 7.26 | 6.82 | 5.25 |
About The Company
Established in 2019, Asston Pharmaceuticals Limited is a pharmaceutical business dealing with the export of healthcare products worldwide.
The firm deals with a wide array of products like tablets, capsules, sachets, and syrups. Its product line covers different therapeutic classes like analgesics, antibiotics, antifungals, vitamins, etc.
The company makes direct sales medicines and also on a contract manufacturing or loan license, majorly operating on a principle-to-principle basis with different marketers.The company is certified by both State and Central FDA, NQA (Nuclear Quality Assurance) accredited, and adheres to Quality Management System (QMS) guidelines in terms of high-quality production.
Products:
Albendazole USP 400 mg: Albendazole USP 400 mg is a higher strength of Albendazole, a broad-spectrum anthelmintic (anti-worm) medication which is used for the treatment of different parasitic worm infections.
Diclofenac 100 mg: Diclofenac 100 mg is a particular strength of Diclofenac, a widely used nonsteroidal anti-inflammatory drug (NSAID).
Ibuprofen, paracetamol: Ibuprofen and Paracetamol (Acetaminophen) are two frequently used over-the-counter medications, typically used to relieve pain and decrease fever.
Ferrovit Syrup: For the management of vitamin and mineral deficiencies.
As of 3 July 2025, there are 46 Permanent staff and 6 contractual staff in the different departments.
Asston Pharmaceuticals - Promoter(s)
Pre Issue Share Holding: 68.76%
Post Issue Share Holding: 50.66%
- Dr. Ashish Narayan Sakalkar
- Saili Jayaram More
- Sachin Chandrakant Badakh
Asston Pharmaceuticals IPO - Issue Objectives
- Funding capital expenditure requirements towards acquiring machinery in the manufacturing unit
- Funding the incremental working capital requirements of the Company
- Repayment and/or prepayment, in part or full, of certain of the outstanding borrowings availed by the Company
- General Corporate Purposes
Other Details
Asston Pharmaceuticals
4th Floor, Office No. A-431 Balaji Bhavan, Plot No 42A Sector-11 CBD Belapur, Navi Mumbai, Thane, Navi Mumbai, Maharashtra, 400614Phone: +91 22 49731411
Email: info@asstonpharmaceuticals.com
Maashitla Securities Private Limited
Phone: +91-11-45121795-96
Email: ipo@maashitla.com
Website: https://maashitla.com/allotment-status/public-issues
Asston Pharmaceuticals IPO - FAQs
Ans. Asston Pharmaceuticals Limited IPO is a SME IPO. The issue is priced at ₹115-123 per equity share. The minimum order quantity is 1000 Shares. The IPO opens on Jul 9, 2025, and closes on Jul 11, 2025. Maashitla Securities Private Limited is the registrar for the IPO. The shares are proposed to be listed on SME BSE.
Ans. The Asston Pharmaceuticals Limited IPO opens on Jul 9, 2025 and closes on Jul 11, 2025.
Ans. The size of Asston Pharmaceuticals Limited IPO is 22,41,000 shares(aggregating up to ₹27.56 Cr).
Ans. The IPO price band is set between ₹115-123 per equity share.
Ans. To apply for Asston Pharmaceuticals Limited IPO IPO, follow the steps given below:
- - Open the IPO Ji App or Website
- - Find Asston Pharmaceuticals Limited IPO in the List of IPOs
- - Press "Apply" Button
- - Select Your Demat Account
- - Select Your Shares Quantity and Submit
- - Track Your IPO Status
Ans. The share allotment date of Asston Pharmaceuticals Limited IPO is Jul 14, 2025.
Ans. The Asston Pharmaceuticals Limited IPO will be listed on Jul 16, 2025.
Ans. Follow the steps to check the allotment status for Asston Pharmaceuticals Limited IPO here.
